For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled patient-efficacy study of this exact supplier preparation was verified.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Mechanistic or cellular bioregulator research cannot establish a clinical benefit for this supplier product.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
HeLa cells and deoxyribooligonucleotide/DNA assays; no treated patients.
Reported findings. Labelled-peptide nuclear/cytoplasmic fluorescence and sequence-dependent nucleic-acid interactions were reported.
Nonresponse. No testosterone, fertility or patient benefit outcome was measured.
Harms. Human adverse outcomes or safety were not measured.
Limits. FITC labelling, fluorescence quenching and laboratory exposure limit inference about intact commercial peptide uptake. An inconsistent discussion sentence involving alanine does not override the KEDG identity stated in methods. Mechanistic interactions are not evidence of clinical androgen effects.
Preparation: Experimental Lys-Glu-Asp-Gly (KEDG); FITC-labelled peptide for HeLa exposure plus intact-peptide cell-free nucleic-acid assays. Route: Cell culture and cell-free incubation; no therapeutic delivery route.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Clinical observation
Efficacy of testosterone synthesis inductor application Testagen in androgenic deficiency in patients with chronic abacterial prostatitis
36 men aged 38–49 with chronic abacterial prostatitis IIIA and low testosterone; 20 add-on recipients versus 16 standard-treatment recipients.
Reported findings. Authors reported symptom/uroflow and testosterone improvements during 30-day treatment, with larger reported changes in the add-on group.
Nonresponse. Both groups improved; testosterone significance annotations compare with baseline rather than establishing a between-group treatment effect.
Harms. Adverse-event outcomes and systematic harms assessment were not reported; absence of reporting is not demonstrated safety.
Limits. Randomization/blinding were not described; tamsulosin and rectal diclofenac were co-interventions. The table supplies one baseline testosterone value of 7.1 nmol/L and post-treatment values of 7.5 standard versus 9.8 add-on; these are not group-specific baseline changes or a verified causal effect. Baseline leukocyte count is 20.8 in body versus 28.2 in the table; inconsistent time-to-peak wording also limits interpretation. This oral complex is not verified as the injectable catalog KEDG preparation. ClinicalTrials.gov NCT02733133 concerns topical Testagen TDS 5% testosterone, an unrelated compound; it must not support this product.
Preparation: FirmaVita oral food-supplement capsules containing AKS-S peptide complex listing lysine, glutamate, aspartate and glycine; purified KEDG identity/equivalence is unverified. Route: Oral supplement added to standard treatment; not injectable purified Testagen.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.